Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Photo by Adobe Stock/HealthDay News The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.

Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use ...

Women using tirzepatide (Zepbound) lost more weight if they also were taking hormone therapy — 17% of body weight lost versus 14% after a median 18 months, researchers reported Saturday at the ...

As part of a new campaign, Whitley is partnering with Zepbound to break down the stigma surrounding obesity and inspire others to seek support and treatment.

The combination is probably why tirzepatide is so effective. In a clinical trial published in 2022 by Aronne and his colleagues, more than 2500 adults with obesity, but not diabetes, took either a ...